# A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

> **NCT07227168** · PHASE1 · RECRUITING · sponsor: **Sutro Biopharma, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma HNSCC
- Non-Small Cell Lung Cancer NSCLC
- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Cervical Cancer
- Endometrial Cancer
- Urothelial Cancer

## Interventions

- **DRUG:** STRO-004
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07227168
- **Lead sponsor:** Sutro Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2027-12
- **Final completion:** 2028-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227168, "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07227168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*